• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于诊断肝脂肪变性的 M 及 XL 探头,能否使用相同的受控衰减参数截断值?

Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?

机构信息

Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Institute of Digestive Disease, The Chinese University of Hong Kong, Sha Tin, Hong Kong.

出版信息

J Gastroenterol Hepatol. 2018 Oct;33(10):1787-1794. doi: 10.1111/jgh.14150. Epub 2018 May 7.

DOI:10.1111/jgh.14150
PMID:29603365
Abstract

BACKGROUND AND AIM

There are limited studies on controlled attenuation parameter (CAP) using Fibroscan XL probe for the diagnosis of hepatic steatosis grade. The aim of this study was to determine whether previously defined optimal cut-offs for CAP using the M probe could be applied for the XL probe.

METHODS

Adult patients with chronic liver disease who had a liver biopsy and examination with both the M and XL probes were included. Previously defined optimal cut-offs for CAP using the M probe were used for the diagnosis of steatosis grades ≥S1, ≥S2, and S3 (248, 268, and 280 dB/m, respectively).

RESULTS

Data for 180 patients were analyzed (mean age 53.7 ± 10.8 years; central obesity 84.5%; non-alcoholic fatty liver disease 86.7%). The distribution of steatosis grades was S0, 9.4%; S1, 28.3%; S2, 43.9%, and S3, 18.3%. The sensitivity, specificity, positive predictive value, and negative predictive value of CAP using the M/XL probe for the diagnosis of steatosis grade ≥S1 was 93.9%/93.3%, 58.8%/58.8%, 95.6%/95.6%, and 50.0%/47.6%, respectively. These values were 94.6%/94.6%, 41.2%/44.1%, 72.6%/73.6%, and 82.4%/83.3%, respectively, for ≥S2, and 87.9%/87.9%, 27.2%/27.9%, 21.3%/21.5%, and 90.9%/91.1%, respectively, for S3.

CONCLUSION

The same cut-off values for CAP may be used for the M and XL probes for the diagnosis of hepatic steatosis grade.

摘要

背景与目的

使用 Fibroscan XL 探头进行受控衰减参数 (CAP) 检测诊断肝脂肪变程度的研究较少。本研究旨在确定先前使用 M 探头定义的 CAP 最佳截断值是否可应用于 XL 探头。

方法

纳入接受肝脏活检且同时接受 M 和 XL 探头检查的慢性肝病成年患者。采用先前使用 M 探头定义的 CAP 最佳截断值,分别诊断脂肪变程度≥S1、≥S2 和 S3(248、268 和 280dB/m)。

结果

共分析了 180 例患者的数据(平均年龄 53.7±10.8 岁;中心性肥胖 84.5%;非酒精性脂肪性肝病 86.7%)。脂肪变程度分布为 S0 9.4%、S1 28.3%、S2 43.9%和 S3 18.3%。使用 M/XL 探头诊断脂肪变程度≥S1 的 CAP 的敏感性、特异性、阳性预测值和阴性预测值分别为 93.9%/93.3%、58.8%/58.8%、95.6%/95.6%和 50.0%/47.6%。这些值分别为≥S2 时的 94.6%/94.6%、41.2%/44.1%、72.6%/73.6%和 82.4%/83.3%,S3 时的 87.9%/87.9%、27.2%/27.9%、21.3%/21.5%和 90.9%/91.1%。

结论

M 和 XL 探头用于诊断肝脂肪变程度时,CAP 的相同截断值可能适用。

相似文献

1
Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?用于诊断肝脂肪变性的 M 及 XL 探头,能否使用相同的受控衰减参数截断值?
J Gastroenterol Hepatol. 2018 Oct;33(10):1787-1794. doi: 10.1111/jgh.14150. Epub 2018 May 7.
2
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.用于非酒精性脂肪性肝病中肝脂肪变性检测和定量的受控衰减参数
J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557.
3
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.使用受控衰减参数(CAP)和瞬时弹性成像技术进行非侵入性诊断肝脂肪变性。
Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x.
4
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.用于非酒精性脂肪性肝病中脂肪变性诊断的受控衰减参数
J Gastroenterol Hepatol. 2016 Apr;31(4):848-55. doi: 10.1111/jgh.13219.
5
Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.控制衰减参数评估肝脂肪变性与肝组织学的比较:单中心真实经验。
Swiss Med Wkly. 2019 Apr 26;149:w20077. doi: 10.4414/smw.2019.20077. eCollection 2019 Apr 22.
6
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.使用 M 和 XL 探头的受控衰减参数评估肝脂肪变性:一项个体患者数据荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):185-198. doi: 10.1016/S2468-1253(20)30357-5. Epub 2021 Jan 16.
7
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.肝纤维化无创诊断技术评估非酒精性脂肪性肝病患者肝脏脂肪变及纤维化的准确性。
Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25.
8
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.中国患者肝脏脂肪变性非侵入性评估的受控衰减参数
World J Gastroenterol. 2014 Apr 28;20(16):4702-11. doi: 10.3748/wjg.v20.i16.4702.
9
Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.瞬时弹性成像测量控制衰减参数对肝脂肪变性无创评估的诊断准确性:一项前瞻性研究
J Gastrointestin Liver Dis. 2015 Mar;24(1):35-42. doi: 10.15403/jgld.2014.1121.mlp.
10
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.控制衰减参数(CAP)在慢性肝病患者肝脂肪变性检测中的应用:一项对韩国本地人群的前瞻性研究。
Liver Int. 2014 Jan;34(1):102-9. doi: 10.1111/liv.12282. Epub 2013 Sep 13.

引用本文的文献

1
A prospective comparison of two ultrasound attenuation imaging modes using different frequencies for assessing hepatic steatosis.使用不同频率的两种超声衰减成像模式评估肝脂肪变性的前瞻性比较。
Ultrasonography. 2025 May;44(3):202-211. doi: 10.14366/usg.24223. Epub 2025 Mar 6.
2
Diagnostic accuracy of ultrasound-derived fat fraction for the detection and quantification of hepatic steatosis in patients with liver biopsy.超声衍生脂肪分数对肝活检患者肝脂肪变性检测及定量的诊断准确性
J Med Ultrason (2001). 2025 Jan;52(1):85-94. doi: 10.1007/s10396-024-01472-6. Epub 2024 Jun 25.
3
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes.
1型糖尿病患者非酒精性脂肪性肝病非侵入性检测的患病率、危险因素及诊断准确性
JHEP Rep. 2023 Apr 7;5(7):100753. doi: 10.1016/j.jhepr.2023.100753. eCollection 2023 Jul.
4
Non-invasive assessment of metabolic dysfunction-associated fatty liver disease.代谢功能障碍相关脂肪性肝病的非侵入性评估
Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221139614. doi: 10.1177/20420188221139614. eCollection 2022.
5
Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal.评估肝脏脂肪变性的超声方法:批判性评价
Diagnostics (Basel). 2022 Sep 22;12(10):2287. doi: 10.3390/diagnostics12102287.
6
Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.糖尿病非酒精性脂肪性肝病患者补充烟酰胺:随机对照试验。
Ther Adv Chronic Dis. 2022 Feb 23;13:20406223221077958. doi: 10.1177/20406223221077958. eCollection 2022.
7
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).2021年成人非酒精性脂肪性肝病:意大利肝脏研究协会(AISF)、意大利糖尿病学会(SID)和意大利肥胖学会(SIO)的临床实践指南
Eat Weight Disord. 2022 Jun;27(5):1603-1619. doi: 10.1007/s40519-021-01287-1. Epub 2021 Dec 16.
8
NAFLD in type 1 diabetes: overrated or underappreciated?1型糖尿病中的非酒精性脂肪性肝病:被高估还是被低估?
Ther Adv Endocrinol Metab. 2021 Nov 23;12:20420188211055557. doi: 10.1177/20420188211055557. eCollection 2021.
9
Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease.应用 FibroTouch 与 Fibroscan 检测慢性肝病患者的衰减参数与肝硬度值。
PLoS One. 2021 May 3;16(5):e0250300. doi: 10.1371/journal.pone.0250300. eCollection 2021.
10
The Role of Elastography in Non-Alcoholic Fatty Liver Disease.弹性成像在非酒精性脂肪性肝病中的作用
Curr Health Sci J. 2020 Jul-Sep;46(3):255-269. doi: 10.12865/CHSJ.46.03.07. Epub 2020 Sep 30.